Categories: CancerNews

RaySearch Laboratories: Interim report July – September 2024

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ — 

THIRD QUARTER (JULY – SEPTEMBER 2024)

  • Order intake SEK 253.4 M (240.7)
  • Net sales SEK 293.3 (252.9)
  • Operating profit SEK 61.8 M (28,6)
  • Profit after tax SEK 45.4 M (21,6)
  • Earnings per share before/after dilution SEK 1.32 (0.63)
  • Cash flow from operating activities SEK 60.5 M (124.4)
  • Order backlog SEK 1,732.0 M (1,966.3) at the end of the period

NINE MONTHS (JANUARY – SEPTEMBER 2024)

  • Order intake SEK 782.1 M (686.5)
  • Net sales SEK 869.4 M (722.5)
  • Operating profit SEK 186.9 M (70.5)
  • Profit after tax SEK 143.5 M (50.0)
  • Earnings per share before/after dilution SEK 4.19 (1.46)
  • Cash flow from operating activities SEK 382.3 M (340.2)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

  • Connect Proton Therapy Center in the USA has placed an order for RayStation
  • Iridium Network first center in the world to use RayCare with TrueBeam to treat a patient

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

  • GenesisCare in the UK has placed an order for RayStation
  • RaySearch now has more than 100 RayStation customers in China
  • Three centers in the French Unicancer network choose RayStation
  • Nina Grönberg has been appointed as the new CFO and will take office in January 2025
  • Institut Curie selects RayStation for proton planning
  • The Board has decided to raise the target for the operating margin to at least 25 (20) percent by 2026

WEBCAST

CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for July-September 2024 in a webcast to be held in English on Friday, November 8, 2024, at 10:00 a.m. CET.

Link to webcast: RaySearch Q3, 2024

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on November 8, 2024, at 7:45 a.m. CET.

FOR MORE INFORMATION, PLEASE CONTACT:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/interim-report-july—september-2024,c4063330

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-july–september-2024-302299745.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

4 hours ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

7 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

10 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

13 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

13 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

13 hours ago